Trials / No Longer Available
No Longer AvailableNCT01947608
Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Novartis-sponsored, open-label, multi-center, interventional ETP to provide LDK378 to patients with ALK (+)NSCLC, who have been pre-treated with an ALK inhibitor; except in countries where ALK inhibitors are not approved or available. The protocol will further evaluate the safety of LDK378 in patients with ALK(+) NSCLC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LDK378 | 750 mg. orally |
Timeline
- First posted
- 2013-09-20
- Last updated
- 2020-11-03
Locations
50 sites across 10 countries: United States, Argentina, Colombia, Hong Kong, India, Jordan, Mexico, Philippines, South Korea, Thailand
Source: ClinicalTrials.gov record NCT01947608. Inclusion in this directory is not an endorsement.